Joseph Stringer

Stock Analyst at Needham

(4.89)
# 303
Out of 5,134 analysts
627
Total ratings
48%
Success rate
23.7%
Average return

Stocks Rated by Joseph Stringer

Gilead Sciences
Oct 30, 2026
Reiterated: Buy
Price Target: $170 → $200
Current: $168.08
Upside: +18.99%
Camp4 Therapeutics
Oct 15, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $3.80
Upside: +110.53%
Vaxcyte
Oct 5, 2026
Rated: Buy
Price Target: $110 → $122
Current: $63.37
Upside: +92.52%
Shattuck Labs
Oct 2, 2026
Rated: Buy
Price Target: $17 → $19
Current: $4.65
Upside: +308.60%
Vir Biotechnology
Sep 28, 2026
Reiterated: Buy
Price Target: $18
Current: $9.96
Upside: +80.72%
Ionis Pharmaceuticals
Sep 23, 2026
Reiterated: Buy
Price Target: $86
Current: $29.06
Upside: +195.94%
Alnylam Pharmaceuticals
Sep 17, 2026
Reiterated: Buy
Price Target: $357
Current: $165.04
Upside: +116.31%
BioAge Labs
Sep 14, 2026
Reiterated: Buy
Price Target: $35
Current: $5.55
Upside: +530.63%
InflaRx
Sep 14, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $1.17
Upside: +583.76%
Moderna
Aug 19, 2026
Reiterated: Hold
Price Target: n/a
Current: $223.37
Upside: -
Reiterated: Buy
Price Target: $25
Current: $3.92
Upside: +537.76%
Reiterated: Hold
Price Target: n/a
Current: $0.697
Upside: -
Reiterated: Buy
Price Target: $130
Current: $115.02
Upside: +13.02%
Reiterated: Buy
Price Target: $40
Current: $26.68
Upside: +49.93%
Reiterated: Hold
Price Target: n/a
Current: $538.60
Upside: -
Reiterated: Buy
Price Target: $28 → $22
Current: $6.06
Upside: +263.04%
Rated: Hold
Price Target: n/a
Current: $1.79
Upside: n/a
Rated: Hold
Price Target: n/a
Current: $1.18
Upside: n/a
Rated: Buy
Price Target: $30 → $26
Current: $18.75
Upside: n/a
Rated: Hold
Price Target: n/a
Current: $167.40
Upside: n/a
Rated: Buy
Price Target: $170
Current: $42.24
Upside: n/a